UY28400A1 - Metabolito - Google Patents
MetabolitoInfo
- Publication number
- UY28400A1 UY28400A1 UY28400A UY28400A UY28400A1 UY 28400 A1 UY28400 A1 UY 28400A1 UY 28400 A UY28400 A UY 28400A UY 28400 A UY28400 A UY 28400A UY 28400 A1 UY28400 A1 UY 28400A1
- Authority
- UY
- Uruguay
- Prior art keywords
- disorders
- pharmaceutically acceptable
- bipolar
- formula
- effective amount
- Prior art date
Links
- 239000002207 metabolite Substances 0.000 title 1
- 208000024891 symptom Diseases 0.000 abstract 3
- 208000019901 Anxiety disease Diseases 0.000 abstract 2
- 208000020925 Bipolar disease Diseases 0.000 abstract 2
- 230000036506 anxiety Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010001497 Agitation Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 206010020400 Hostility Diseases 0.000 abstract 1
- 206010026749 Mania Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 238000013019 agitation Methods 0.000 abstract 1
- 208000028683 bipolar I disease Diseases 0.000 abstract 1
- 208000025307 bipolar depression Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un método para tratar ansiedad, agitación, hostilidad, pánico, trastornos alimenticios, síntomas afectivos, síntomas relacionados con el humor, síntomas psicóticos negativos y positivos comúnmente asociados a esquizofrenia, demencia, ansiedad, depresión, trastornos del humor, trastornos bipolares, manía bipolar, depresión bipolar, trastornos cognitivos, trastornos neurodegenerativos que comprende administrar una cantidad eficaz de Fórmula I o su sal farmacéuticamente aceptable. En otro aspecto, la invneción proporciona una composición farmacéutica que comprende una cantidad eficaz de Fórmula I o su sal farmacéuticamente aceptable y al menos una portador o diluyente farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48436503P | 2003-07-02 | 2003-07-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY28400A1 true UY28400A1 (es) | 2005-01-31 |
Family
ID=33563981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY28400A UY28400A1 (es) | 2003-07-02 | 2004-07-02 | Metabolito |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20050026900A1 (es) |
| EP (1) | EP1644005B1 (es) |
| JP (1) | JP2007516193A (es) |
| KR (1) | KR20060082037A (es) |
| CN (1) | CN1816339B (es) |
| AR (1) | AR045004A1 (es) |
| AT (1) | ATE477803T1 (es) |
| AU (1) | AU2004253334A1 (es) |
| BR (1) | BRPI0412127A (es) |
| CA (1) | CA2531284A1 (es) |
| DE (1) | DE602004028739D1 (es) |
| ES (1) | ES2349091T3 (es) |
| IL (1) | IL172616A0 (es) |
| IS (1) | IS8283A (es) |
| MX (1) | MXPA05013869A (es) |
| NO (1) | NO20060556L (es) |
| RU (1) | RU2005141060A (es) |
| TW (1) | TW200509944A (es) |
| UY (1) | UY28400A1 (es) |
| WO (1) | WO2005002586A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2000141A1 (en) * | 2002-03-20 | 2008-12-10 | Teva Pharmaceutical Industries Ltd. | Methods for preparing crystalline quetiapine hemifumarate |
| DE602004020263D1 (de) | 2003-12-22 | 2009-05-07 | Acadia Pharm Inc | Amino-substituierte diaryläa,dücyclohepten- analoga als muscarinische agonisten und verfahren zur behandlung von neuropsychiatrischen erkrankungen |
| WO2008021463A2 (en) * | 2006-08-15 | 2008-02-21 | Acadia Pharmaceuticals, Inc. | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| US20060081361A1 (en) * | 2004-09-13 | 2006-04-20 | Gabbey Lawrence W | Oil cooler with integral filter |
| JP2008526839A (ja) * | 2005-01-07 | 2008-07-24 | アストラゼネカ・アクチエボラーグ | １１−ピペラジン−１−イルジベンゾ［ｂ，ｆ］［１，４］チアゼピン又はその薬学的に許容される塩の新規な使用及び経口医薬組成物への新規な使用 |
| CA2599922A1 (en) * | 2005-04-04 | 2006-10-12 | Acadia Pharmaceuticals Inc. | Use of n-desmethylclozapine and related compounds as dopamine stabilizing agents |
| EP1869007A1 (en) * | 2005-04-14 | 2007-12-26 | Teva Pharmaceutical Industries Ltd | Process for preparing quetiapine fumarate |
| WO2007004234A1 (en) * | 2005-07-04 | 2007-01-11 | Usv Limited | A PROCESS FOR THE PREPARATION OF 2-[2-(4-DIBENZO[b,f] [L,4] THIAZEPIN-11-yl-1- PIPERAZINYL)ETHOXY] ETHANOL FUMARATE |
| JP2009516705A (ja) * | 2005-11-18 | 2009-04-23 | アストラゼネカ・アクチエボラーグ | 塩の形態 |
| EP1951693A4 (en) * | 2005-11-18 | 2012-05-30 | Astrazeneca Ab | SOLID FORMULATIONS |
| US8389510B2 (en) | 2005-11-18 | 2013-03-05 | Astrazeneca Ab | Crystalline forms |
| WO2008116144A1 (en) * | 2007-03-22 | 2008-09-25 | Astrazeneca Ab | Methods of treating mood disorders |
| WO2008079839A1 (en) * | 2006-12-20 | 2008-07-03 | Astrazeneca Ab | Compounds and uses thereof |
| JP2009516708A (ja) * | 2005-11-18 | 2009-04-23 | アストラゼネカ・アクチエボラーグ | 液体製剤 |
| JP2009516706A (ja) * | 2005-11-18 | 2009-04-23 | アストラゼネカ・アクチエボラーグ | 結晶形 |
| WO2008118141A2 (en) * | 2006-10-17 | 2008-10-02 | Acadia Pharmaceuticals Inc. | Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy |
| EP2120957A4 (en) * | 2006-12-20 | 2011-05-04 | Astrazeneca Ab | COMPOUNDS AND USES THEREOF |
| US20100093699A1 (en) * | 2006-12-20 | 2010-04-15 | Astrazeneca Ab | Compounds and uses thereof - 177 |
| US20110183963A1 (en) | 2009-12-31 | 2011-07-28 | Travis Mickle | Amino Acid Conjugates of Quetiapine, Process for Making and Using the Same |
| LT2544536T (lt) | 2010-03-11 | 2019-02-25 | Kempharm, Inc. | Kvetiapino riebalų rūgšties konjugatai, jų gamybos būdas ir panaudojimas |
| CN102552128B (zh) * | 2012-02-28 | 2013-09-18 | 陆荣政 | 一种富马酸喹硫平注射液及其制备方法 |
| US9993486B1 (en) | 2017-06-19 | 2018-06-12 | Tlc Therapeutics, Llc | Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL140242B (nl) * | 1963-03-01 | 1973-11-15 | Wander Ag Dr A | Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen. |
| GB1192812A (en) * | 1966-05-20 | 1970-05-20 | American Cyanamid Co | 2-Chloro-11-(1-Piperazinyl)Dibenz[b,f]-[1,4]Oxazepine, Non-Toxic Acid Addition Salts thereof, and Therapeutic Compositions containing said Oxazepine or Salts |
| US3539573A (en) * | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| US3966949A (en) * | 1973-10-12 | 1976-06-29 | Richardson-Merrell Inc. | Pharmaceutical compositions and preparing same |
| GB8607684D0 (en) * | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| US5750566A (en) * | 1994-08-12 | 1998-05-12 | Eli Lilly And Company | Synthetic excitatory amino acids |
| WO2000010572A1 (en) * | 1998-08-18 | 2000-03-02 | Sepracor Inc. | Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine |
| US20040224942A1 (en) * | 2003-01-23 | 2004-11-11 | Weiner David M. | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
-
2004
- 2004-06-28 AU AU2004253334A patent/AU2004253334A1/en not_active Abandoned
- 2004-06-28 WO PCT/GB2004/002783 patent/WO2005002586A1/en not_active Ceased
- 2004-06-28 ES ES04743131T patent/ES2349091T3/es not_active Expired - Lifetime
- 2004-06-28 EP EP04743131A patent/EP1644005B1/en not_active Expired - Lifetime
- 2004-06-28 AT AT04743131T patent/ATE477803T1/de not_active IP Right Cessation
- 2004-06-28 RU RU2005141060/15A patent/RU2005141060A/ru not_active Application Discontinuation
- 2004-06-28 CN CN2004800188710A patent/CN1816339B/zh not_active Expired - Fee Related
- 2004-06-28 JP JP2006518324A patent/JP2007516193A/ja not_active Ceased
- 2004-06-28 MX MXPA05013869A patent/MXPA05013869A/es not_active Application Discontinuation
- 2004-06-28 KR KR1020057025264A patent/KR20060082037A/ko not_active Withdrawn
- 2004-06-28 CA CA002531284A patent/CA2531284A1/en not_active Abandoned
- 2004-06-28 BR BRPI0412127-9A patent/BRPI0412127A/pt not_active IP Right Cessation
- 2004-06-28 DE DE602004028739T patent/DE602004028739D1/de not_active Expired - Lifetime
- 2004-07-01 US US10/883,024 patent/US20050026900A1/en not_active Abandoned
- 2004-07-02 AR ARP040102345A patent/AR045004A1/es not_active Application Discontinuation
- 2004-07-02 TW TW093120058A patent/TW200509944A/zh unknown
- 2004-07-02 UY UY28400A patent/UY28400A1/es not_active Application Discontinuation
-
2005
- 2005-12-15 IL IL172616A patent/IL172616A0/en unknown
-
2006
- 2006-02-01 IS IS8283A patent/IS8283A/is unknown
- 2006-02-02 NO NO20060556A patent/NO20060556L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20060556L (no) | 2006-04-03 |
| WO2005002586A1 (en) | 2005-01-13 |
| AU2004253334A1 (en) | 2005-01-13 |
| MXPA05013869A (es) | 2006-02-28 |
| US20050026900A1 (en) | 2005-02-03 |
| TW200509944A (en) | 2005-03-16 |
| RU2005141060A (ru) | 2006-07-27 |
| BRPI0412127A (pt) | 2006-08-15 |
| JP2007516193A (ja) | 2007-06-21 |
| IL172616A0 (en) | 2006-04-10 |
| CN1816339B (zh) | 2010-12-15 |
| CN1816339A (zh) | 2006-08-09 |
| IS8283A (is) | 2006-02-01 |
| EP1644005A1 (en) | 2006-04-12 |
| KR20060082037A (ko) | 2006-07-14 |
| EP1644005B1 (en) | 2010-08-18 |
| DE602004028739D1 (de) | 2010-09-30 |
| AR045004A1 (es) | 2005-10-12 |
| WO2005002586A8 (en) | 2006-02-09 |
| CA2531284A1 (en) | 2005-01-13 |
| ATE477803T1 (de) | 2010-09-15 |
| ES2349091T3 (es) | 2010-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY28400A1 (es) | Metabolito | |
| GT200100183A (es) | Derivados de quinolina y quinazolina. | |
| BRPI0412909A (pt) | uso de rnai inibindo atividade de parp para a fabricação de um medicamento para o tratamento de cáncer | |
| AR032086A1 (es) | Combinaciones de farmacos | |
| ECSP099476A (es) | Compuestos carboxamida y su uso como inhibidores de calpaína | |
| UY26958A1 (es) | Nuevos agentes anticolinérgicos que se pueden emplear como medicamentos así como procedimiento para su preparación | |
| CY1111206T1 (el) | Βενζοθειοφαινια υποκατεστημενα με πιπεραζινη για την αγωγη διανοητικων διαταραχων | |
| BR0314393A (pt) | Piperazinas heterocìclicas substituìdas para o tratamento de esquizofrenia | |
| UY27300A1 (es) | Nuevos derivados de quinolina | |
| BR0314299A (pt) | Derivados de pirrolidona como inibidores de mao-b | |
| BRPI0507609A (pt) | combinações terapêuticas de anti-psicóticos atìpicos com antagonistas de fator de liberação de corticotropina | |
| ECSP055719A (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos | |
| Simeon et al. | A retrospective chart review of risperidone use in treatment-resistant children and adolescents with psychiatric disorders | |
| PE20110711A1 (es) | Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmaceuticamente aceptables de la misma | |
| MY152919A (en) | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders | |
| BRPI0411936A (pt) | composto, processo para a sua preparação, composição farmacêutica que comprende o mesmo, utilização de um composto, métodos para o tratamento e profilaxia de distúrbios do sistema nervoso central, alimentares e obesidade | |
| MY142804A (en) | Nk1 antagonists | |
| UY27018A1 (es) | Derivados de la pirimidina | |
| UY29924A1 (es) | Medicamentos en base a 11-(4-(2-(2-hidroxietoxi)etil)-1-piperazinil)dibenzo-(b,f)(1,4)tiazepina y sus sales farmacéuticamente aceptables | |
| PE20011049A1 (es) | Combinacion de farmacos para el tratamiento de la depresion y trastornos relacionados que comprenden mirtazapina | |
| UY28401A1 (es) | Metabolito | |
| BRPI0518785A2 (pt) | composto de anel de 7 membros e mÉtodo de produÇço e aplicaÇço farmacÊutica do mesmo | |
| PA8600101A1 (es) | Derivados de 3-azabiciclo[3.2.1]octano | |
| DE60327634D1 (de) | Mittel zur behandlung des integrationsdysfunktionssyndroms | |
| BR0317714A (pt) | Oxazóis como realçadores de mglur1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20150602 |